3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Warts
1
Neutropenia
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Leukopenia
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Infections
1
Immunologic Deficiency Syndromes
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Acquired Immunodeficiency Syndrome
1
Interventions
venetoclax
91
Azacitidine
75
Cytarabine
68
Specimen Handling
45
fludarabine
44
Biopsy
32
Cyclophosphamide
29
Daunorubicin
27
fludarabine phosphate
25
Injections
25
Decitabine
25
Idarubicin
24
Busulfan
20
Granulocyte Colony-Stimulating Factor
19
Whole-Body Irradiation
18
Mycophenolic Acid
18
Tacrolimus
17
Melphalan
17
decitabine and cedazuridine drug combination
16
gilteritinib
14
Stem Cell Transplantation
14
CPX-351
14
Mitoxantrone
13
Peripheral Blood Stem Cell Transplantation
11
Magnetic Resonance Spectroscopy
11
Filgrastim
11
Etoposide
11
Cladribine
11
ivosidenib
10
revumenib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Acute
×
plerixafor
×
90 days
×
Clear all
NCT06158828
2026-05-05
ABCD-NK
Washington University School of Medicine
Phase 1/2
Recruiting
68 enrolled